Botulinum toxin A in the treatment of upper and lower limb spasticity

a systematic review of randomized controlled trials.
  • 1.82 MB
  • 4429 Downloads
  • English

Canadian Coordinating Office for Health Technology Assessment , Ottawa
Botulinum toxin -- Therapeutic use., Spasms -- Chemotherapy., Dystonia -- Chemothe
Other titlesBotulinum toxin A for upper and lower limb spasiticity.
SeriesTechnology overview -- issue 18, Technology overview (Ottawa, Ont.) -- issue 18
The Physical Object
Pagination8 p.
ID Numbers
Open LibraryOL19167367M

Botulinum Toxin in the Treatment of Upper and Lower Limb Spasticity Post Stroke Deinnervating lower extremity muscles with botulinum toxin reduces spasticity, but has not been shown to improve.

The purpose of this open study was to find out whether botulinum toxin A (BTX-A) relieves the signs and symptoms of chronic limb spasticity. The study comprised 40 patients, aged years, with moderate to severe spasticity of the upper (13) or lower limbs (27) refractory to conventional physical and medical by: What is botulinum toxin.

Botulinum toxin is produced by the bacteria, Clostridium botulinum. (FDA) has approved Botox, Dysport, and Xeomin for the treatment of upper limb spasticity in adults, specifically spasticity at the elbow, wrist and fingers.

Botox and Dysport have been approved for treatment of distal (lower) leg muscles in adults. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal spasticity in people with CP.

Objectives: To evaluate the effectiveness and safety of BoNT-A compared to other treatments used in the management of lower limb spasticity in children with CP.

Botulinum toxin (BoNT) therapy aims to reduce upper limb spasticity, one of the positive features of the upper motor neuron syndrome. Botulinum toxin type A (BoNT-A) is a safe and effective treatment for upper and RA E1 E2 Strong lower limb spasticity, resulting in both passive and active functional gains: •Commissioning of spasticity management programmes should include provision for use of BoNT-A injection, when administered in line with the recommendations below.

Details Botulinum toxin A in the treatment of upper and lower limb spasticity PDF

Disability Assessment Scale after Botulinum toxin A treatment for upper limb spasticity. Jpn J Compr Rehabil Sci ; 8: Objective: We investigated the effectof botulinum toxin type A for upper limb spasticity on activities of daily living using the Disability Assessment Scale (DAS). Botulinum toxin type A has been considered the gold standard treatment for spasticity and movement disorders, with effica Spasticity with muscle paresis and loss of dexterity is a common feature of upper motor neuron syndrome due to injuries or the pyramidal tract in several neurological conditions.

BOTOX®for injection is indicated for the treatment of upper limb spasticity in adult patients to decrease the severity of increased muscle tone in elbow, wrist, finger, and thumb flexors (biceps, flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum sublimis, adductor pollicis, and flexor pollicis longus).

Botulinum toxin type A (hereafter referred to as botulinum toxin) is a valuable treatment option for functional problems related to spasticity following brain injury.

This article reviews the treatment of upper and lower limb spasticity in neurological rehabilitation. Botulinum toxin A proved effective in several placebo-controlled studies reducing muscle tone, easing hand hygiene and nursing, improving upper limb motor functions and gait ability.

The effects are reversible and the toxin is well tolerated. Background and Purpose Recent studies have been made of the novel treatment of lower limb spasticity after stroke with botulinum toxin A, and the results were based mostly on the clinical assessment made before and after treatment.

Most of the large-scale studies on botulinum toxin have been related to upper and lower limb spasticity. The usefulness of BoNT in the management of spasticity secondary to a variety of clinical conditions is increasing. It is now well accepted for the management of movement disorders, particularly dystonia.

Botulinum toxin type A PBS listing extended. After an extensive campaign by the authors of an MJA Perspective and the Rehabilitation Medicine Society of Australia and New Zealand, the Pharmaceutical Benefits Scheme (PBS) listing for botulinum toxin type A will be extended to include adults with lower limb focal spasticity after a Anupam Datta Gupta, a rehabilitation.

Research design and methods: In a multicentre, randomised, double-blind, parallel-group, placebo-controlled study, patients with upper limb spasticity were randomised to receive a single treatment with lower-dose (– U) or higher-dose (– U) BoNTA or placebo into upper limb muscles.

The trial used one neurotoxin, Botox ( unit vial), which has approval for upper limb spasticity after stroke. Muscles injected and units per muscle were recorded. Participants in the experimental group received the InTENSE program immediately after the botulinum toxin-A injection.

In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose. Contraindications. Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin.

AbstractIntroduction: Spasticity is a significant problem following stroke. Although there is extensive research examining the efficacy of botulinum toxin as a treatment, there are challenges in implementing its use.

Methods: The results from previously published randomized controlled trials and systematic reviews examining the use of botulinum toxin as a treatment for poststroke spasticity of.

The pertinent literature lacks overt technical data for optimal upper limb muscle botulinum toxin injections using ultrasound (US) imaging. Therefore, this guide is prepared for the commonly injected muscles of the upper limb and the shoulder girdle mainly in spasticity.

It includes clinical informa. Botulinum toxin type A injections for the treatment of lower limb spasm in cerebral palsy Cerebral palsy (CP) is a non-progressive lifelong condition resulting from damage to the newborn brain. Most infants have spasms (spasticity) affecting at least one leg that prevents normal movement.

XEOMIN Is Indicated for the Treatment of Upper Limb Spasticity in Children (≥2 years), Excluding Spasticity Caused by Cerebral Palsy The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.

Description Botulinum toxin A in the treatment of upper and lower limb spasticity EPUB

Safety and effectiveness of XEOMIN in patients. Botulinum toxin is used in the treatment of overactive bladder, urinary incontinence, chronic migraines, spasticity (contractions causing muscle stiffness), cervical dystonia (neck muscles contracting involuntarily), severe underarm sweating, eyelid spasms, crossed eyes, and drooling.

It is also used for the treatment of facial lines and wrinkles. Successful treatments to improve post-stroke spasticity are required. Objective: To assess the relevant medical literature related to the use of botulinum toxin type A and post-stroke spasticity of the upper limb. Methods: Literature review utilizing Medline with keywords of botulinum toxin, stroke, spasticity, and upper extremity since AbobotulinumtoxinA is the first and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity.

In the U.S., the FDA approves the text of the labels of prescription medicines and for which medical conditions the drug manufacturer may sell the drug. Randomized controlled trials have shown that botulinum toxin type A can decrease upper limb spasticity and improve the ease of performing basic upper limb.

It examines the neurophysiology of spasticity, measurement of outcome, and the newer treatment techniques, such as phenol and alcohol nerve blocks and botulinum toxin injections. More invasive procedures, including intrathecal baclofen and surgical intervention for more complex and severe spasticity are covered in detail.5/5(1).

Download Botulinum toxin A in the treatment of upper and lower limb spasticity FB2

Introduction. Upper-limb spasticity is characterized by overactivity in muscles after injury to the central nervous system. When left untreated, poststroke spasticity (PSS) can lead to contractures, pain and deformity, involuntary movement, and greater functional impairments (eg, reduced mobility, self-care, dressing) and medical complications (eg, skin maceration and pressure sores).

Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev, (4):CD Cochrane Database Syst. There is high‐level evidence that injection of botulinum toxin A (BoNT‐A), in combination with occupational therapy, improves upper limb outcomes in children with cerebral palsy (CP) 1 However, studies evaluating BoNT‐A as an adjunct to occupational therapy have primarily focused on the effect of BoNT‐A and, thus, have provided limited information on post‐injection therapies.

treat increased muscle stiffness in the arm because of upper limb spasticity in adults. treat increased muscle stiffness in the arm in children 2 to 17 years of age with upper limb spasticity, excluding spasticity caused by cerebral palsy. treat the abnormal head position and neck pain with cervical dystonia (CD) in adults.

IncobotulinumtoxinA (Xeomin®) is a botulinum neurotoxin type A with established efficacy in the treatment of upper-limb spasticity in adults. This retrospective case series in a university hospital setting aimed to elucidate the safety and tolerability of incobotulinumtoxinA for treatment of spasticity in children with cerebral palsy.

Participants received incobotulinumtoxinA injections up to. James S. Huntley, Lyndon J. Bradley, The Evidence Base for Botulinum Toxin Injection for the Treatment of Cerebral Palsy–Related Spasticity in the Lower Limb: The Long-Term Effects, Paediatric Orthopaedics, /, (), ().Dosing for upper limb spasticity: between Units and Units Dosing for lower limb spasticity: up to Units ® The maximum recommended total dose per treatment session (upper and lower limb combined) in adults is Units Re-treatment, based on return of clinical symptoms, should not occur in intervals of less than 12 weeks.